Because CysLT1R antagonists and GPBAR1 agonists have shown efficacy in treating NASH, we have further characterized the lead compound in this series for its efficacy toward a preclinical model of NAFLD/NASH. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.